Hasil Pencarian  ::  Simpan CSV :: Kembali

"Kanker serviks merupakan salah satu jenis kanker dengan prevalensi dan penyebab kematian tertinggi di dunia. Salah satu metode pengobatan kanker serviks adalah kemoterapi dengan menggunakan doxorubicin. Doxorubicin merupakan salah satu senyawa obat kelas antrasiklin yang dapat menghambat kerja enzim Topoisomerase II. Topoisomerase II diketahui memiliki peranan dalam mempertahankan struktur kromosom. Namun, hingga saat ini pengaruh doxorubicin terhadap kromosom sel kanker belum diketahui. Perubahan struktur kromosom yang terdeteksi lebih cepat dapat menjadi pertimbangan dalam optimasi dosis doxorubicin pada kemoterapi kanker serviks. Penelitian ini bertujuan untuk mengetahui pengaruh pemberian doxorubicin terhadap jumlah, panjang, dan luas area kromosom sel HeLa menggunakan mikroskop cahaya. Kultur sel HeLa ditumbuhkan dan dipanen kromosomnya di atas coverslip. Kultur sel HeLa kemudian diberi perlakuan doxorubicin dengan konsentrasi 4 μg/mL selama 24 jam. Kromosom metafase sel HeLa kontrol dan perlakuan kemudian dipanen dan diwarnai dengan pewarna Giemsa untuk pengamatan dengan mikroskop cahaya. Hasil pengamatan kromosom sel HeLa kontrol menunjukkan jumlah kromosom 41—75 kromosom per sel, panjang kromosom sebesar 2—5 μm, dan luas area sebesar 4—15 μm2 per kromosom. Kromosom metafase tidak diperoleh dari sel yang diberi perlakuan doxorubicin. Hal tersebut kemungkinan disebabkan oleh pengaruh inhibisi doxorubicin terhadap aktivitas enzim Topoisomerase II sehingga terjadi kerusakan DNA yang memicu apoptosis sel.

---

Cervical cancer is one of the cancers with the highest prevalence in the world. One of the treatments commonly used for cervical cancer is chemotherapy using doxorubicin. Doxorubicin is one of the compounds belong to the antracycline class which responsible for inhibiting the Topoisomerase II enzyme. Topoisomerase II has also been reported to be correlated with the maintenance of chromosome structure. Nevertheless, to date, the information about the effects of doxorubicin on chromosome structure has yet to be revealed. Alterations in chromosome structure which are detected more quickly can be a consideration in optimizing the dose of doxorubicin in cervical cancer chemotherapy. This study aimed to evaluate the effects of doxorubicin on the HeLa chromosome number, length, and area using a light microscope. HeLa cell was cultured and treated with 4 μg/mL doxorubicin for 24 hours. The cells were then harvested on the coverslips. Metaphase chromosomes of HeLa cells treated with doxorubicin and the control were stained with Giemsa and finally observed by using a light microscope. The results obtained from this study showed that the number, length, and area of the control chromosomes were 41—75 chromosomes per cell, 2—5 μm, and 4—15 μm2, respectively. Furthermore, the metaphase chromosome from the cells treated with doxorubicin could not be obtained. This result indicated that the doxorubicin treatment might inhibits the activity of the Topoisomerase II enzyme, causing DNA damage that triggers cell apoptosis."

"DNA topoisomerases represent an essential family of DNA processing enzymes and a large number of topoisomerase inhibitors are used clinically for the treatment of various human cancers. Novels drugs are in clinical development both against type I and type II topoisomerases. The book will include basic biochemical and structural reviews for the cancer-relevant topoisomerases. It will describe how topoisomerase dysfunctions can damage the genome and increase the risk of cancers, and the involvement of topoisomerases in programmed cell death. The book will also present the various topoisomerase inhibitors in clinical use and development and their molecular and cellular mechanisms of action."